Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study

Abstract

In this population-based study, 21 % of the patients had metastatic disease at presentation, with a decreasing trend over the study period. During 5-year follow-up, 20 % of the primary non-metastatic patients had recurrent disease. Of the patients with recurrence, half were given systemic oncological treatment and 17 % underwent metastasectomy.

Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma

“…Concerning all stages of RCC, the most common locations of the first recurrence were lung (54%), lymph nodes (22%), bone (20%), and liver (15%). 75 Other population-based studies have found similar results. 76 Chin et al 77 reported that tumour stage plays an important role in timing of recurrence, with T1 tumours generally recurring between 3 and 4 years following resection.…”

“…79 Among several studies regarding RCC surveillance, the latest postnephrectomy recurrence in the lungs, abdomen, and bone was approximately 6 years, 8 years, and 12 years, respectively. [75][76][77][78] In a cohort from a single center, most kidney cancer patients treated for lung metastasis were diagnosed with metachronous lesions with the following features: solitary mass, one affected lung, and measured more than 2 cm. Multivariate analysis confirmed a significant effect of radical surgery on the survival in these pateints.…”

“…[73][74][75] Dabestani et al 75 reported 35% recurrence rate after mean followup duration of 5 years in a population-based study of patients with T2 disease who underwent RN or PN. Retrospective analysis of single institution with similar followup showed 16% of recurrence, diagnosed between 24 and 57 months after RN, and the lung was the main…”

Nivolumab as the new standard of metastatic kidney cancer treatment

“…Ежегодно от рака почки умирают около 8 тыс. россиян [1].Несмотря на совершенствование методов диагнос-тики и миграции стадии заболевания в сторону повы-шения частоты выявления локализованных форм опу-холи, около трети пациентов имеют синхронные отдаленные метастазы на момент установления диаг-ноза и у 20-25 % развиваются метахронные метастазы в разные сроки после хирургического лечения [2,3].Наиболее распространенным (85 %) вариантом рака почки является светлоклеточный, характеризую-щийся мутацией гена VHL. Существующие достижения в терапии и рекомендации по лечению диссеминиро-ванного рака почки относятся именно к светлоклеточ-ному типу.…”

“…Несмотря на совершенствование методов диагнос-тики и миграции стадии заболевания в сторону повы-шения частоты выявления локализованных форм опу-холи, около трети пациентов имеют синхронные отдаленные метастазы на момент установления диаг-ноза и у 20-25 % развиваются метахронные метастазы в разные сроки после хирургического лечения [2,3].…”